MCID: MGR028
MIFTS: 46

Migraine with or Without Aura 1

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine with or Without Aura 1

MalaCards integrated aliases for Migraine with or Without Aura 1:

Name: Migraine with or Without Aura 1 54
Migraine 54 12 51 29 52 41 14
Migraine Without Aura 54 12 42 14
Common Migraine 12 52 69
Migraine Disorders 42 69
Migraine Variant 12 69
Migraine with or Without Aura, Susceptibility to, 1 13
Migraine with or Without Aura 12
Migraine Disorder 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
headache duration 4-72 hours
aggravated by physical activity
genetic heterogeneity, see, e.g., mgr2 , mgr3 , mgr4 , mgr5 , mgr6


HPO:

32
migraine with or without aura 1:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Migraine with or Without Aura 1

OMIM : 54
Migraine is the most common type of chronic, episodic headache, as summarized by Featherstone (1985). One locus for migraine with or without aura (MGR1) has been identified on chromosome 4q24. Other loci for migraine have been identified on 6p21.1-p12.2 (MGR3; 607498), 14q21.2-q22.3 (MGR4; 607501), 19p13 (MGR5; 607508), 1q31 (MGR6; 607516), 15q11-q13 (MGR7; 609179), 5q21 (with or without aura, MGR8, 609570; with aura, MGR9, 609670), 17p13 (MGR10; 610208), 18q12 (MGR11; 610209), 10q22-q23 (MGR12; 611706), and the X chromosome (MGR2; 300125). Mutation in the KCNK18 gene (613655) on chromosome 10q25 causes migraine with aura (MGR13; 613656). A subtype of autosomal dominant migraine with aura (MA), familial hemiplegic migraine (FHM; see 141500), is caused by mutation in the CACNA1A gene (601011) on chromosome 19p13 (FHM1; 141500), by mutation in the ATP1A2 gene (182340) on chromosome 1q21 (FHM2; 602481), or by mutation in the SCN1A gene (182389) on chromosome 2q24 (FHM3; 609634). Another locus for FHM has been mapped to chromosome 1q31 (FHM4; see 607516). There is evidence that a polymorphism in the estrogen receptor gene (ESR1; 133430.0005) and a polymorphism in the TNF gene (191160.0004) may confer susceptibility to migraine. A polymorphism in the endothelin receptor type A gene (EDNRA; 131243.0001) may confer resistance to migraine. (157300)

MalaCards based summary : Migraine with or Without Aura 1, also known as migraine, is related to familial hemiplegic migraine and migraine with aura, and has symptoms including vomiting, photophobia and migraine with aura. An important gene associated with Migraine with or Without Aura 1 is EDNRA (Endothelin Receptor Type A). The drugs Sumatriptan and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and pituitary.

Disease Ontology : 12 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing.

MedlinePlus : 41 if you suffer from migraine headaches, you're not alone. about 12 percent of the u.s. population gets them. migraines are recurring attacks of moderate to severe pain. the pain is throbbing or pulsing, and is often on one side of the head. during migraines, people are very sensitive to light and sound. they may also become nauseated and vomit. migraine is three times more common in women than in men. some people can tell when they are about to have a migraine because they see flashing lights or zigzag lines or they temporarily lose their vision. many things can trigger a migraine. these include anxiety stress lack of food or sleep exposure to light hormonal changes (in women) doctors used to believe migraines were linked to the opening and narrowing of blood vessels in the head. now they believe the cause is related to genes that control the activity of some brain cells. medicines can help prevent migraine attacks or help relieve symptoms of attacks when they happen. for many people, treatments to relieve stress can also help. nih: national institute of neurological disorders and stroke

NINDS : 51 The pain of a migraine headache is often described as an intense pulsing or throbbing pain in one area of the head. However, it is much more; the International Headache Society diagnoses a migraine by its pain and number of attacks (at least 5, lasting 4-72 hours if untreated), and additional symptoms including nausea and/or vomiting, or sensitivity to both light and sound. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. Roughly one-third of affected individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, anxiety, hormonal changes, bright or flashing lights, lack of food or sleep, and dietary substances.  Migraine in some women may relate to changes in hormones and hormonal levels during their menstrual cycle.  For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine has a genetic cause.

Related Diseases for Migraine with or Without Aura 1

Diseases related to Migraine with or Without Aura 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
id Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 12.5
2 migraine with aura 12.3
3 hemiplegic migraine 12.2
4 migraine, familial hemiplegic, 2 12.2
5 migraine, familial hemiplegic, 3 12.2
6 migraine with brainstem aura 12.2
7 migraine, familial hemiplegic, 1 12.2
8 sporadic hemiplegic migraine 12.2
9 migraine, with or without aura 13 12.1
10 migraine with or without aura 5 11.9
11 familial or sporadic hemiplegic migraine 11.9
12 migraine with aura 9 11.7
13 migraine without aura 4 11.7
14 migraine with aura 7 11.7
15 migraine with or without aura 3 11.7
16 migraine with or without aura, susceptibility 13 11.7
17 migraine with or without aura 6 11.7
18 cyclic vomiting syndrome 11.5
19 headache 11.3
20 epilepsy, familial temporal lobe, 4 11.3
21 handl syndrome 11.3
22 episodic ataxia 11.2
23 alternating hemiplegia of childhood 11.2
24 trochleitis 11.2
25 hemicrania continua 11.1
26 carotidynia 11.1
27 cluster headache 11.0
28 episodic ataxia, type 2 11.0
29 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1 10.9
30 paroxysmal hemicrania 10.9
31 new daily-persistent headache 10.9
32 vasculopathy, retinal, with cerebral leukodystrophy 10.9
33 alpha-methylacyl-coa racemase deficiency 10.8
34 visual snow syndrome 10.7
35 dystonia 9 10.7
36 brain small vessel disease with or without ocular anomalies 10.7
37 peroxisome biogenesis disorder 14b 10.7
38 valproate embryopathy, susceptibility to 10.7
39 convulsions, familial infantile, with paroxysmal choreoathetosis 10.7
40 sturge-weber syndrome, somatic, mosaic 10.6
41 cadasil 1 10.6
42 ariboflavinosis 10.6
43 benign epilepsy with centrotemporal spikes 10.6
44 stormorken syndrome 10.6
45 alternating hemiplegia of childhood 2 10.6
46 autosomal dominant optic atrophy plus syndrome 10.6
47 paroxysmal exertion-induced dyskinesia 10.6
48 phosphoglycerate kinase deficiency 10.6
49 col4a1-related brain small-vessel disease 10.6
50 hemiplegia alterans 10.6

Comorbidity relations with Migraine with or Without Aura 1 via Phenotypic Disease Network (PDN):


Anxiety Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with or Without Aura 1:



Diseases related to Migraine with or Without Aura 1

Symptoms & Phenotypes for Migraine with or Without Aura 1

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Gastroin testinal:
vomiting
nausea

Neurologic- Central Nervous System:
photophobia
migraine with aura
migraine without aura
phonophobia
headache is unilateral
more

Clinical features from OMIM:

157300

Human phenotypes related to Migraine with or Without Aura 1:

32 (show all 6)
id Description HPO Frequency HPO Source Accession
1 vomiting 32 HP:0002013
2 photophobia 32 HP:0000613
3 migraine with aura 32 HP:0002077
4 nausea 32 HP:0002018
5 migraine without aura 32 HP:0002083
6 phonophobia 32 HP:0002183

UMLS symptoms related to Migraine with or Without Aura 1:


back pain, headache, hemiplegia, nausea, pain, sciatica, seizures, syncope, tremor, chronic pain, scotoma, scintillating, vertigo/dizziness, hemicrania, sleeplessness, recurrent paroxysmal headache

Drugs & Therapeutics for Migraine with or Without Aura 1

Drugs for Migraine with or Without Aura 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sumatriptan Approved, Investigational Phase 4,Phase 3,Phase 2 103628-46-2 5358
2
Naproxen Approved, Vet_approved Phase 4,Phase 3 22204-53-1 1302 156391
3
Rizatriptan Approved Phase 4,Phase 3 145202-66-0, 144034-80-0 5078
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
6
Topiramate Approved Phase 4 97240-79-4 5284627
7
Almotriptan Approved, Investigational Phase 4,Phase 3 154323-57-6, 181183-52-8 123606
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
9
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
10 Serotonin Agents Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2
12 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2
16 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1
19 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2
20 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
21 Pharmaceutical Solutions Phase 4
22 Adrenergic Agents Phase 4,Phase 2,Phase 3
23 Adrenergic Antagonists Phase 4,Phase 2,Phase 3
24 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
25 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Anticonvulsants Phase 4,Phase 2
27 Antihypertensive Agents Phase 4,Phase 2,Phase 3
28 Anti-Obesity Agents Phase 4
29 Neuroprotective Agents Phase 4,Early Phase 1
30 Protective Agents Phase 4,Early Phase 1
31
Eletriptan Approved, Investigational Phase 3 143322-58-1 77993
32
Zolmitriptan Approved, Investigational Phase 3 139264-17-8 441240 60857
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
34
Candesartan Approved Phase 2, Phase 3 139481-59-7 2541
35
Caffeine Approved, Nutraceutical Phase 3 58-08-2 2519
36
Angiotensin II Investigational Phase 2, Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
37 Antiemetics Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 3
39 Emetics Phase 3
40 Opiate Alkaloids Phase 3
41 Oxazolidinones Phase 3
42 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
43 Autonomic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
44 BB 1101 Phase 3,Phase 1,Phase 2
45 Dexamethasone acetate Phase 3,Phase 1,Phase 2 1177-87-3
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 glucocorticoids Phase 3,Phase 1,Phase 2
48 HIV Protease Inhibitors Phase 3,Phase 1,Phase 2
49 Hormone Antagonists Phase 3,Phase 1,Phase 2
50 Hormones Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 70)

id Name Status NCT ID Phase Drugs
1 Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
2 Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds Completed NCT02287376 Phase 4 Diclofenac Potassium for Oral Solution
3 An Efficacy and Tolerability Study of Topiramate in Participants With Migraine Completed NCT01060111 Phase 4 Topiramate Standard;Topiramate Slow;Propranolol booster
4 A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache Completed NCT00210509 Phase 4 almotriptan malate
5 A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Completed NCT00792636 Phase 4 sumatriptan and naproxen sodium combination tablet;sumatriptan tablet;naproxen sodium tablet
6 MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant Unknown status NCT00283738 Phase 2, Phase 3
7 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Completed NCT00383162 Phase 3 Combination Product (sumatriptan succinate / naproxen sodium);Placebo
8 Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Completed NCT01986270 Phase 3 Placebo;Eletriptan 40 mg;Eletriptan 80 mg;Sumatriptan 25 mg;Sumatriptan 50 mg
9 Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Completed NCT01986088 Phase 3 Placebo;Eletriptan 40 mg;Eletriptan 80 mg;Sumatriptan 50 mg;Sumatriptan 100 mg
10 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) Completed NCT00442936 Phase 3 Telcagepant potassium 150 mg;Telcagepant potassium 300 mg;Zolmitriptan 5 mg;Placebo to telcagepant 150 mg;Placebo to tecagepant 300 mg;Placebo to zolmitriptan 5 mg;Rescue medication
11 Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) Completed NCT00483704 Phase 3 Telcagepant 140 mg;Talcagepant 280 mg;Placebo
12 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
13 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Completed NCT00382993 Phase 3 Placebo;Combination Product (sumatriptan succinate/naproxen sodium)
14 Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Completed NCT01989936 Phase 3 Placebo;Eletriptan 40 mg;Eletriptan 80 mg
15 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines Completed NCT00122278 Phase 3 dexamethasone 10mg IV
16 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
17 Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura Completed NCT00449540 Phase 3
18 Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
19 Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura Completed NCT01667679 Phase 3 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally;OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
20 Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine Completed NCT01462812 Phase 3 Sumatriptan;Placebo
21 A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents Completed NCT00210483 Phase 3 almotriptan malate
22 Migraine Study in Adolescent Patients Completed NCT00843024 Phase 3 Sumatriptan and Naproxen Sodium;Placebo
23 Candesartan Versus Propranolol for Migraine Prevention Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
24 A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) Completed NCT00894556 Phase 3 rizatriptan;Comparator: Placebo;Comparator: Sumatriptan
25 Oral ALLOD-2 vs. Components and vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1) Recruiting NCT03061734 Phase 2, Phase 3 ALLOD-2;ALLOD-2H;Component A (regular dose);Component B;Placebo
26 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting NCT02867709 Phase 3 Ubrogepant;Placebo-matching Ubrogepant
27 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting NCT02828020 Phase 3 Ubrogepant;Placebo-matching Ubrogepant
28 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention Recruiting NCT02848326 Phase 2, Phase 3 AGN-241689;Placebo-matching AGN-241689
29 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Active, not recruiting NCT02873221 Phase 3 Ubrogepant;Placebo-matching Ubrogepant;Usual Care
30 DFN-11 Injection in Episodic Migraine With or Without Aura Active, not recruiting NCT02569853 Phase 3 DFN-11
31 A Safety Study of LY2951742 in Participants With Migraine, With or Without Aura Active, not recruiting NCT02614287 Phase 3 LY2951742
32 ESCAPE Migraine Trial Terminated NCT00267371 Phase 3 Medical management/current medications per standard of care by personal physician.
33 Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
34 Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine Completed NCT01820559 Phase 2 Placebo;ESL 1200 mg;ESL 800 mg
35 Staccato Prochlorperazine in Patients With Migraine Headache Completed NCT00610428 Phase 2 Staccato Prochlorperazine;Staccato Prochlorperazine;Staccato Placebo
36 Tonabersat in the Prophylaxis of Migraine With Aura Completed NCT00332007 Phase 2 Tonabersat;Placebo
37 Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
38 Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
39 Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
40 Staccato® Prochlorperazine for Inhalation in Migraine Completed NCT00422812 Phase 2 Prochlorperazine thermal aerosol
41 A Study of LY2951742 in Participants With Migraine Completed NCT01625988 Phase 2 LY2951742;Placebo
42 Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine Completed NCT02057315 Phase 1, Phase 2 ELS-M11;Placebo
43 Study of NXN 188 for the Treatment of Migraine With Aura Completed NCT00920686 Phase 2 NXN-188;placebo;sumatriptan succinate
44 Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches Recruiting NCT02777359 Phase 2
45 Treatment of Chronic Migraine Headaches. Recruiting NCT03220113 Phase 1, Phase 2
46 A Study in Migraine Prevention Terminated NCT01184508 Phase 2 Placebo;LY2300559
47 ADX10059 Migraine Prevention Study Terminated NCT00820105 Phase 2 ADX10059;ADX10059;ADX10059;ADX10059 Matching Placebo
48 The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients Unknown status NCT02364453 PACAP38
49 Efficacy of Sumatriptan With Naprosyn in Migraine With Aura Unknown status NCT00893594 sumatriptan with naprosyn;placebo
50 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486

Search NIH Clinical Center for Migraine with or Without Aura 1

Cochrane evidence based reviews: migraine without aura

Genetic Tests for Migraine with or Without Aura 1

Genetic tests related to Migraine with or Without Aura 1:

id Genetic test Affiliating Genes
1 Migraine 29

Anatomical Context for Migraine with or Without Aura 1

MalaCards organs/tissues related to Migraine with or Without Aura 1:

39
Brain, Bone, Pituitary

Publications for Migraine with or Without Aura 1

Variations for Migraine with or Without Aura 1

Copy number variations for Migraine with or Without Aura 1 from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39736 10 118956999 118969809 Copy number KCNK18 Migraine

Expression for Migraine with or Without Aura 1

Search GEO for disease gene expression data for Migraine with or Without Aura 1.

Pathways for Migraine with or Without Aura 1

GO Terms for Migraine with or Without Aura 1

Sources for Migraine with or Without Aura 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....